Patents by Inventor Ross Kedl

Ross Kedl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20200087370
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: June 24, 2019
    Publication date: March 19, 2020
    Inventors: Ross KEDL, Phillip J. Sanchez, Catherine Haluszczak
  • Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
    Patent number: 10329338
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: June 25, 2019
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF
    Publication number: 20160015803
    Abstract: Immunostimulatory combination are provided comprising: (i) a TLR agonist, (ii) a CD40 agonist, and (iii) an antigen, wherein said antigen consists of one or more antigenic peptides which range in size from 6-14 amino acids in length, wherein these moieties are each present in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. The use of such short peptides unexpectedly enhances CD8+ T cell immunity.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 21, 2016
    Inventor: Ross Kedl
  • CD40 Agonist Antibody /Type 1 Interferon Synergistic Adjuvant Combination, Conjugates Containing and Use Thereof as a Therapeutic to Enhance Cellular Immunity
    Publication number: 20150376253
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: July 1, 2015
    Publication date: December 31, 2015
    Inventors: Ross KEDL, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 9095608
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: August 4, 2015
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 8361471
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: January 29, 2013
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20120251494
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: February 16, 2012
    Publication date: October 4, 2012
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 8137672
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: March 20, 2012
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20110286968
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: June 21, 2011
    Publication date: November 24, 2011
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 7993648
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: August 9, 2011
    Assignee: The Regents of the Universitry of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
    Publication number: 20110182847
    Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).
    Type: Application
    Filed: June 16, 2008
    Publication date: July 28, 2011
    Inventors: Randolph Noelle, Ross Kedl, Cory Ahonen
  • CD40 AGONIST ANTIBODY/TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20100317111
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Application
    Filed: July 29, 2010
    Publication date: December 16, 2010
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • TLR AGONIST (FLAGELLIN)/CD40 AGONIST/ANTIGEN PROTEIN AND DNA CONJUGATES AND USE THEREOF FOR INDUCING SYNERGISTIC ENHANCEMENT IN IMMUNITY
    Publication number: 20100291109
    Abstract: Fusion proteins and DNA conjugates are disclosed which contain a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided.
    Type: Application
    Filed: June 9, 2010
    Publication date: November 18, 2010
    Inventor: Ross Kedl
  • TLR AGONIST (FLAGELLIN)/CD40 AGONIST/ANTIGEN PROTEIN AND DNA CONJUGATES AND USE THEREOF FOR INDUCING SYNERGISTIC ENHANCEMENT IN IMMUNITY
    Publication number: 20090004194
    Abstract: Fusion proteins and DNA conjugates are disclosed which contain a TLR/CD40/agonist and optional antigen combination. The use of these protein and DNA conjugates as immune adjuvants and as vaccines for treatment of various chronic diseases such as HIV infection is also provided.
    Type: Application
    Filed: March 1, 2007
    Publication date: January 1, 2009
    Applicant: Regents of the University of Colorado
    Inventor: Ross Kedl
  • CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
    Publication number: 20080050340
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylacetic and therapeutic) is also provided.
    Type: Application
    Filed: May 3, 2007
    Publication date: February 28, 2008
    Applicant: REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Ross Kedl, Phillip Sanchez, Catherine Haluszczak
  • Delivery of immune response modifier compounds
    Publication number: 20060195067
    Abstract: Delivery of one or more immune response modifiers (IRMs) across a biological barrier by the use of a microneedle device.
    Type: Application
    Filed: August 25, 2004
    Publication date: August 31, 2006
    Inventors: James Wolter, Ross Kedl
  • Method of eliciting an immune response against HIV
    Publication number: 20060045885
    Abstract: The present invention provides methods of eliciting an immune response against HIV. Generally, the method includes administering to a subject an effective amount of an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 2, 2006
    Inventors: Ross Kedl, Robert Seder
  • HIV immunostimulatory compositions
    Publication number: 20060045886
    Abstract: The present invention provides an IRM-HIV composition that includes an IRM portion paired with an HIV antigenic portion.
    Type: Application
    Filed: August 26, 2005
    Publication date: March 2, 2006
    Inventor: Ross Kedl
  • Immunomodulatory combinations
    Publication number: 20050158325
    Abstract: The present invention provides immunomodulatory combinations that includes an IRM component and a therapeutic agent, each in an amount that, when in combination with the other, is effective for inducing an immune response in a subject.
    Type: Application
    Filed: December 30, 2004
    Publication date: July 21, 2005
    Inventors: David Hammerbeck, Ross Kedl, Richard Miller, Mark Tomai, John Vasilakos
  • Immunostimulatory combinations and treatments
    Publication number: 20050048072
    Abstract: The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an IRM compound and a pharmaceutical composition. Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject.
    Type: Application
    Filed: August 25, 2004
    Publication date: March 3, 2005
    Inventors: Ross Kedl, Mark Tomai, John Vasilakos